|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Therapies to modulate gut microbiota:Past,present and future显示文摘The human gut microbiota comprises of a complex and diverse array of microorganisms,and over the years the interaction between human diseases and the gut microbiota has become a subject of growing interest.Disturbed microbial milieu in the gastrointestinal tract is central to the pathogenesis of several diseases including antibiotic-associated diarrhea and Clostridioides difficile infection(CDI).Manipulation of this microbial milieu to restore balance by microbial replacement therapies has proven to be a safe and effective treatment for recurrent CDI.There is considerable heterogeneity in various aspects of stool processing and administration for fecal microbiota transplantation(FMT)across different centers globally,and standardized microbioal replacement therapies offer an attractive alternative.The adverse effects associated with FMT are usually mild.However,there is paucity of data on long term safety of FMT and there is a need for further studies in this regard.With our increasing understanding of the host-microbiome interaction,there is immense potential for microbial replacement therapies to emerge as a treatment option for several diseases.The role of microbioal replacement therapies in diseases other than CDI is being extensively studied in ongoing clinical trials and it may be a potential treatment option for inflammatory bowel disease,irritable bowel syndrome,obesity,multidrug resistant infections,and neuropsychiatric illnesses.Fecal microbiota transplantation for non-CDI disease states should currently be limited only to research settings. | Akshita Gupta Srishti Saha Sahil Khanna | 2020 | World Journal of Gastroenterology2020，26，8： | 8 |
| 2 | Role of Joshi's external stabilization system with percutaneous screw fixation in high-energy tibial condylar fractures associated with severe soft tissue injuries显示文摘Purpose: The treatment of high-energy tibial condylar fractures which are associated with severe soft tissue injuries remains contentious and challenging. In this study, we assessed the results of Joshi's external stabilization system (JESS) by using the principle of ligamentotaxis and percutaneous screw fixation for managing high-energy tibial condylar fractures associated with severe soft tissue injuries. Methods: Between June 2008 and June 2010, 25 consecutive patients who were 17-71 years (mean, 39.7), underwent the JESS fixation for high-energy tibial condylar fractures associated with severe soft tissue injuries. Out of 25 patients, 2 were lost during follow-up and in 1 case early removal of frame was done, leaving 22 cases for final follow-up. Among them, 11 had poor skin condition with abrasions and blisters and 2 were open injuries (Gustilo-Anderson grade I & 11). The injury mechanisms were motor vehicle accidents (n - 19), fall from a height (n = 2) and assault (n - 1). The fractures were classified according to Schatzker classification system. Results: There were 7 type-V, 14 type-Vl and 1 type-IV Schatzker's tibial plateau fractures. The average interval between the injury and surgery was 6.8 days (range 2-13). The average hospital stay was 13 days (range, 7-22). The average interval between the surgery and full weight bearing was 13.6 weeks (range 11-20). The average range of knee flexion was 121° (range 105°-135°). The normal extension of the knee was observed in 20 patients, and an extensor lag of 5°-8° was noted in 2 patients. The complications included superficial pin tract infections (n 4) with no knee stiffness. Conclusion: JESS with lag screw fixation combines the benefit of traction, external fixation, and limited internal fixation, at the same time as allowing the ease of access to the soft tissue for wound checks, pin care, dressing changes, measurement of compartment pressure, and the monitoring of the neurovascular status. In a nutshell, JESS along with screw fixation offers a promising alternative treatment for high- energy tibial condylar fractures associated with severe soft tissue injuries. | Ashish Kumar Gupta Rahul Sapra Rakesh Kumar Som Prakash Gupta Devwart Kaushik Sahil Gaba Mahesh Chand Bansal Ratan Lal Dayma | 2015 | Chinese Journal of Traumatology2015，18，6： | 4 |
| 3 | Effect of hy- droxyl - functionalization on the structure and properties of poly- propylene 显示文摘 | Sahil Gupta Xuepei Yuan T C Mike Chung | 2013 | Macromolecules2013，46，14： | 1 |
| 4 | 难辨梭菌感染患儿的结局:一项全国性调查结果显示文摘目的:基于医院和人群的研究都发现,难辨梭菌感染(CDI)的发生率在成人与儿童中均不断上升,但儿童CDI的结局仍不甚明确。我们分析了美国国家出院调查(NHDS)数据,以了解住院患儿CDI情况。方法:提取2005-2009年间的NHDS数据(包括人口统计资料、诊断情况和出院状态),应用ICD-9代码的诊断标准来筛选病例。采用加权单因素和多因素分析来明确CDI发生率及CDI与临床结局[包括住院时间、结肠切除术、各种原因导致的住院病死率及出院转至康复机构(DTCF)]的关系。结果:在13.8百万住院患儿中有46176例出现CDI,中位年龄为3岁,总发生率为33.5/万。CDI的实际发生率在2005-2009年间并没有明显变化(0.24%-0.43%,P=0.64)。单因素分析显示,CDI患儿中位住院时间延长(6 d vs 2 d),肠切除率(OR=2.0,95%CI:1.7-2.4)、病死率(OR=2.5,95% CI:2.3-2.7)和DTCF率(OR=1.6,95%CI:1.6-1.7)增加(均P<0.0001)。按年龄、性别和术前合并症校正后,CDI是长住院时间(校正平均差6.4 d,95% CI:5.4-7.4 d)、高肠切除率(OR=2.1,95% CI:1.8-2.5)、高病死率(OR=2.3,95% CI:2.2-2.5)和高DTCF率(OR=1.7,95% CI:1.6-1.8)的独立且最强的影响因素。排除婴儿后进行亚组分析,结果显示,与未出现CDI的儿童相比,CDI儿童的病死率和DTCF率显著增高,住院时间亦显著延长。结论:尽管对CDI认识不断提高,治疗措施也在不断进步,CDI仍然是一个重要的临床问题,会导致住院患儿住院时间延长,肠切除率、住院病死率和DTCF率增高。 | Arjun Gupta Darrell S Pardi Larry M Baddour Sahil Khanna | 2016 | Gastroenterology Report2016，4，4： | 0 |
| 5 | Role of high dose vitamin C in management of hospitalised COVID-19 patients:A minireview显示文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has emerged as one of the most dreadful viruses the mankind has witnessed.It has caused worldwide havoc and wrecked human life.In our quest to find therapeutic options to counter this threat,several drugs have been tried,with varying success.Certain agents like corticosteroids,some anti-virals and immunosuppressive drugs have been found useful in improving clinical outcomes.Vitamin C,a water-soluble vitamin with good safety profile,has been tried to reduce progression and improve outcomes of patients with coronavirus disease 2019(COVID-19).Because of its anti-oxidant and immunomodulatory properties,the role of vitamin C has expanded well beyond the management of scurvy and it is increasingly been employed in the treatment of critically ill patients with sepsis,septic shock,acute pancreatitis and even cancer.However,in spite of many case series,observational studies and even randomised control trials,the role of vitamin C remains ambiguous.In this review,we will be discussing the scientific rationale and the current clinical evidence for using high dose vitamin C in the management of COVID-19 patients. | Deven Juneja Anish Gupta Sahil Kataria Omender Singh | 2022 | World Journal of Virology2022，11，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员